Who Is Intuitive Surgical (ISRG)?: The Long-Term Story of an “Infrastructure” Company That Makes Surgery Easier Through Robotics

* This report is prepared based on data as of 2026-01-24.

The Business First: What does ISRG do, and why does it earn attractive economics?

Intuitive Surgical (ISRG) provides hospitals with a “complete toolkit that makes surgery easier using robots.” The key point is that the robot is not autonomous. Surgeons control the system, and their hand movements are translated into more precise, steadier motion. The result is that minimally invasive surgery (with a lower physical burden) can be extended to a broader set of patients.

Who are the customers? (buyers, users, and beneficiaries are different)

The practical customers are “hospitals” and the “surgeons who operate within those hospitals.” The purchase decision sits with hospital management, while ongoing day-to-day usage is driven by the front line (physicians and surgical teams). Patients aren’t the buyers, but demand for “less burdensome surgery” supports adoption. In other words, the buyer, the user, and the beneficiary are three different parties.

What does it sell? (the full product and service picture)

• Surgical-assistance robot system (da Vinci): Installed in hospital operating rooms; a platform that supports surgeons’ work through multiple arms, cameras, and related components.
• Consumables and instruments: Proprietary instruments and consumables required for each procedure. Revenue builds as procedure volume rises.
• Maintenance and support (service): Because downtime is highly disruptive, scheduled inspections and rapid repair response are essential. This revenue stream tends to scale with the installed base.
• Pulmonary diagnostic support (Ion): A system that guides a thin catheter to lesions deep in the lung to enable biopsy (specimen collection). There is meaningful room for improvement via software updates, and announced updates include navigation enhancements incorporating AI and integration with imaging equipment.

How does it make money? (“system + per-use charges + upkeep fees”)

ISRG’s revenue model is best summarized as “system + per-use charges + upkeep fees.” Hospitals place the system; each procedure requires proprietary instruments and consumables; and maintenance contracts add up over time. Ion follows a similar pattern, with revenue tied to placements and ongoing utilization.

The power of the model is that revenue can expand naturally as the installed base (number of systems in hospitals) grows and utilization per system (procedure volume) increases. From a performance-driver standpoint, growth in da Vinci procedure volume is typically the central storyline.

Why is it chosen? (value proposition for middle-school level)

ISRG’s value proposition is a “standard toolkit that makes surgery easier and more consistently stable.” For physicians, it supports repeatability through usability, visualization, and precision. For hospitals, building a robotic surgery capability can increase patient appeal. For patients, it can (depending on the case) enable minimally invasive outcomes.

Separately, the trend toward more computing power and added “software functionality,” such as intraoperative insights with da Vinci 5, strengthens the value proposition from “sell the machine and you’re done” to “keep improving how the system is used and how efficiently it runs.”

Growth Engines: What could keep the wind at ISRG’s back?

Structurally, ISRG’s growth drivers consistently come back to “installed base × utilization per system (procedure volume).” Several tailwinds can stack on top of that foundation.

• Robotic surgery broadening from “select hospitals only” to a wider set of hospitals and a broader range of procedures
• Rising procedure volume per system at existing customer sites (higher utilization)
• Faster upgrades (replacements) and incremental placements driven by new models and added functionality
• Greater adoption in pulmonary diagnostics (Ion) (a strong fit with early-detection needs)
• Efforts to standardize sales and support quality, including buying back distributor businesses in Europe and strengthening direct sales

Future pillars (initiatives that could become important even if not core today)

• da Vinci 5: strengthening “real-time intraoperative support” via software. Leveraging computing capability to expand intraoperative information display and review, with an emphasis on efficiency, learning, and operations.
• Ion: navigation improvements using AI and imaging integration. The push to reliably reach smaller, deeper targets aligns with clear clinical needs and could represent meaningful upside.
• da Vinci SP: expanding indications. A system designed for single-port surgery; the broader the indications, the more reasons hospitals have to adopt it.

(Separate) “Internal infrastructure” that supports competitiveness

Surgical robotics only works when “hardware,” “single-use instruments,” “maintenance,” “training,” and “software updates” are tightly integrated. ISRG’s education and operational support (learning systems) that drive sustained usage after installation, along with ongoing software improvements, likely sit at the heart of its competitive position. Expanding a direct sales model also supports long-term competitiveness by standardizing support quality—not just selling systems.

Analogy (just one)

ISRG isn’t a “high-performance cooking robot.” It’s closer to a company that provides a “high-performance cooking station + dedicated tools + maintenance staff” that helps the chef (surgeon) cook better. The surgeon is the protagonist; the tools exist to “reduce mistakes and deliver consistently good outcomes.”

Long-Term Fundamentals: What does this company’s “pattern” look like?

Looking at the long-run numbers, ISRG reads like a hybrid: “close to stable growth (Stalwart), but with a higher growth rate.” The fact that all Lynch classification auto-judgment flags in the dataset are false is mainly because it doesn’t strictly clear the more demanding Fast Grower thresholds (e.g., 5-year EPS growth above 20%, ROE above 15%). In practical terms, it fits well in the “high-quality growth company” bucket.

Long-term revenue and profit trends (the backbone of the growth story)

• Revenue growth (annual CAGR): past 5 years +13.3%, past 10 years +14.6%
• Net income growth (annual CAGR): past 5 years +11.0%, past 10 years +18.7%
• EPS growth (annual CAGR): past 5 years +10.8%, past 10 years +18.0%

Revenue has grown at a double-digit pace over both the past 10 years and the past 5 years, and it’s not a profile dominated by pronounced cyclical swings (sharp drops followed by sharp rebounds). Profit and EPS show “10 years > 5 years,” suggesting stronger growth over the longer window, while the most recent five years look somewhat more moderate. This isn’t a value judgment; it’s best treated as an observed fact driven by the difference in periods.

Profitability (ROE) and long-term margin profile

ROE in the latest FY is 14.1%, and it has been broadly stable over the last 5 years (median 13.5%, reference range 11.8%–14.2%) and the last 10 years (median 14.0%, reference range 12.6%–14.7%). This isn’t a “sky-high ROE” story; it’s a business that wins by staying consistently in the low-to-mid teens.

Cash flow (FCF): the fact that growth has been muted in recent years

• Free cash flow growth (annual CAGR): past 5 years +2.1%, past 10 years +8.8%
• Latest FY FCF margin: 15.6% (the distribution median over the last 5 years is also 15.6%, reference range 14.4%–27.1%)

Relative to profit and revenue, 5-year FCF growth is modest, and annual FCF margins sit toward the lower end of the distribution. The dataset notes that in the latest FY (2024), operating cash flow was $2.415 billion versus capex of $1.111 billion, pointing to a heavy investment burden. That raises the question of whether investment and/or cost increases may be compressing cash-generation headroom (without making a definitive causal claim—first organizing it as an “observed fact”).

Share count: limited dilution over the long term

Shares outstanding increased from approximately 358.5 million in 2019 to approximately 362.0 million in 2024, and at minimum this does not suggest a pattern of “large dilution continuing over a long period.”

Lynch classification: Which “type” is this stock closest to?

In summary, ISRG is best organized as closest to a “Stalwart-leaning growth stock (hybrid)”.

• Rationale: 5-year EPS growth +10.8% (stable-growth range)
• Rationale: 5-year revenue growth +13.3% (double-digit growth)
• Rationale: Latest FY ROE 14.1% (stable in double digits)

Because it doesn’t strictly meet the more demanding Fast Grower thresholds (e.g., 5-year EPS +20%, ROE +15%), positioning it as Stalwart-leaning is reasonable.

Near-Term Momentum: Is the long-term “pattern” still holding?

On a recent TTM basis, growth is running above the long-term (5-year) average, and the momentum classification is “Accelerating.” Even for long-term investors, this section matters as a check that the underlying pattern remains intact.

TTM growth: EPS and revenue are strong

• EPS (TTM) YoY: +24.2% (clearly above 5-year EPS CAGR +10.8%)
• Revenue (TTM) YoY: +20.5% (clearly above 5-year revenue CAGR +13.3%)

While the long-term profile is “stable growth to somewhat higher growth,” the most recent year has been stronger, and this is not a case where “growth has stalled and the Stalwart premise has broken.”

8-quarter (last 2 years) trend: continued upward trajectory is visible

• EPS (last 2 years; 8-quarter CAGR equivalent): +19.9% (strong upward trend)
• Revenue (last 2 years; 8-quarter CAGR equivalent): +17.3% (strong upward trend)

Supplementary margin check: quarterly operating margin

Operating margin over the last several quarters has generally been in the ~30% range, and the direction does not materially conflict with the revenue and profit momentum (noted here only at a directional level).

FCF is difficult to confirm (TTM cannot be calculated)

Because free cash flow (TTM) cannot be calculated, FCF momentum over the last year can’t be assessed. This is not a “good/bad” conclusion; the point is simply that it’s difficult to evaluate with the data for this period.

Meanwhile, over the last 2 years (8-quarter CAGR equivalent), FCF growth of +74.1% is observed. However, because the latest TTM cannot be calculated, it’s more prudent not to conclude that “current momentum is also strong,” and instead keep it framed as “strong numbers are visible over the last two years, but confirmation on a recent TTM basis isn’t possible.”

Financial Soundness: How should we think about bankruptcy risk? (fact-based organization)

Based on the dataset figures, ISRG’s balance sheet reflects extremely low reliance on debt and a substantial cash cushion.

• Debt / equity (latest FY): 0.009 (about 0.9%)
• Net Debt / EBITDA (latest FY): -1.38 (net cash position)
• Cash ratio (latest FY): 2.30

At a minimum, the data don’t suggest the company is “forcing growth through borrowing.” From a bankruptcy-risk standpoint, it can be organized as having significant financial flexibility.

That said, while Net Debt / EBITDA is negative (net cash), relative to the past 5- and 10-year distributions it sits at a less negative level (an upside break versus the distribution). The apparent thickness of cash versus the past remains a point to discuss (separating the fact of being net cash from where it sits within the historical distribution).

Capital Allocation: reinvestment over dividends

ISRG is not a stock where dividends are easy to make central to the investment case. Key indicators for the latest TTM dividend yield, dividend per share, and dividend burden cannot be calculated, which implies it’s difficult to use for income planning (we do not infer or supplement dividend presence or levels).

On an annual (FY) basis, dividend payments of $8 million and dividends per share of $0.0221 were recorded in 2024, but over the long term there are many years with zero or unrecorded dividends, and there is no clear, continuous dividend track record to point to.

Capital allocation appears more focused on reinvestment for growth than on dividends. In the latest FY (2024), capex of $1.111 billion versus operating cash flow of $2.415 billion contributes to the FY FCF margin of 15.6% (toward the lower end of the historical range).

Where Valuation Sits Today (historical comparison only)

Here, without comparing to the market or peers, we focus only on where today’s valuation sits versus ISRG’s own history (primarily the past 5 years, with the past 10 years as context). Price-based metrics are as of a share price of $523.99.

P/E: within the 5-year range, toward the high side versus 10 years

• P/E (TTM): 66.1x
• Past 5 years: median 71.7x, reference range 57.4–79.8x → currently within the range (toward the lower side)
• Past 10 years: median 48.9x, reference range 35.3–73.5x → currently within the range (toward the higher side)

At the same P/E, it reads as “within the normal range” on a 5-year view, but “relatively higher” on a 10-year view. This is a difference in appearance driven by different baselines (distributions) between 5 years and 10 years.

PEG: within the 5-year range but somewhat high; high zone versus 10 years

• PEG (based on TTM growth rate): 2.74x
• Past 5-year range (20–80%): 1.71–3.09x → within the range (closer to the high side within the past 5 years)
• Past 10-year range (20–80%): 1.16–2.95x → within the range but high

Directionally over the last 2 years, PEG includes periods where its position within the distribution shifted toward the lower side (no 2-year range is constructed; direction only).

Free cash flow yield: latest TTM cannot be calculated, so “current position” cannot be placed

Because FCF yield (TTM) cannot be calculated, it isn’t possible to determine where it sits within the past 5- and 10-year ranges or how it moved over the last 2 years. As historical context, the past 5-year median is 1.36% (reference range 1.00%–1.60%) and the past 10-year median is 1.90% (reference range 1.28%–3.32%), but the key point is that a current comparison cannot be made.

ROE: tracking toward the upper end of the historical range

• ROE (latest FY): 14.1%
• Past 5-year range (20–80%): 11.8%–14.2% → within the range (upper side)
• Past 10-year range (20–80%): 12.6%–14.7% → within the range (somewhat upper side)

Directionally over the last 2 years as well, ROE has been tracking on the higher side.

FCF margin: TTM cannot be calculated; on an FY basis it is toward the lower side

Because FCF margin (TTM) cannot be calculated, the TTM-based current position and the last-2-year direction can’t be assessed. As a reference point, the latest FY FCF margin is 15.6%, positioned toward the lower end of the past 5-year distribution and near the lower bound of the past 10-year distribution. Because TTM and FY cover different periods, the appearance can vary, and should be read separately.

Net Debt / EBITDA: net cash, but an “upside break (shallower negative)” versus the historical range

• Net Debt / EBITDA (latest FY): -1.38x (net cash position)
• Past 5-year range (20–80%): -2.64 to -1.83x → currently above the range (toward a shallower negative)
• Past 10-year range (20–80%): -3.90 to -2.05x → currently above the range (same)

This is an inverse metric where “smaller (more negative)” implies a thicker cash position. The current value is negative and indicates net cash, but relative to the historical distribution, cash appears thinner—this is simply the mathematical placement of the current reading (it does not imply an investment view).

Cash Flow Quality: How should we read consistency between EPS and FCF?

Over the long run, EPS and revenue have grown at double-digit rates, while 5-year FCF growth is only +2.1%, and the FY FCF margin sits toward the lower end of the distribution. That raises the possibility of a phase where a gap opens up: “profits grow, but growth in freely usable cash slows.”

However, because recent TTM FCF cannot be calculated, it’s difficult to assess from this dataset whether that gap is widening or narrowing today. The appropriate investor posture is to avoid hard conclusions from short windows and keep monitoring the capex burden and whether conversion from operating cash flow to FCF becomes more stable.

Success Story: Why ISRG has won (the essence)

ISRG’s core value is that it delivers a “complete surgical infrastructure package” that enables surgeons to operate robots and provide more precise, highly reproducible minimally invasive surgery. It’s not a standalone machine; it’s an offering that becomes embedded in hospital workflows—spanning instruments, consumables, maintenance, training, and ongoing software improvements.

In this structure, the adoption decision is made by the hospital, but the decision to keep using the platform sits heavily with the front line (surgeons and surgical teams). The more the front line becomes proficient, case volume rises, and training cycles repeat, the harder the platform becomes to displace—creating a practical barrier to entry. Add in the heavy regulatory, clinical-evidence, and safety requirements, and it becomes difficult for newcomers to “enter and then scale with the same operating density.”

What customers value (Top 3)

• Usability, visualization, and precision: Helps make difficult procedures easier to perform consistently, directly supporting reproducibility.
• Confidence in the full operating package: Instrument supply, maintenance, and training are systematized, reducing the risk of operating-room disruptions.
• Expanded indications and updates: Installed equipment is less likely to become obsolete, and use cases can expand over time.

What customers are dissatisfied with (Top 3)

• Heavy decision-making burden for adoption and expansion: Requires planning not only for capex, but also OR scheduling, staffing, training, and peripheral equipment.
• Terms become a focal point during cost-pressure phases: Depending on country/region, tenders can push price and contract terms to the forefront.
• Misalignment between “installation” and “utilization” is more likely in new domains: As with Ion, there can be phases where utilization grows but placements don’t scale as easily.

Story Durability: Are recent strategies consistent with the winning pattern?

Near-term growth drivers remain “installed base × utilization.” In particular, platform refresh (migration to new models) can act as a driver on the “installed base” side in the current phase. New models aren’t just performance upgrades; for hospitals, they can be investments aimed at “raising utilization / expanding indications / improving training efficiency,” which can then create a chain reaction that increases instrument and consumable pull-through (per-use charges).

That said, Ion has shown periods where utilization rises while new placements grow more slowly (or decline). That may indicate a shift from a “new adoption” phase to a “drive utilization at existing sites” phase. This isn’t inherently good or bad, but it matters because the “way growth is built” may be changing.

Quiet Structural Risks: What can break even when the business looks strong?

ISRG looks like a strong ecosystem-style company, but there are several “hard-to-see” failure points. The right way to frame them is not as isolated negatives, but as factors that can disrupt the model’s chain (installation → utilization → consumables).

1) Deterioration in competitive conditions by region (tenders, local favoritism, pricing pressure)

The idea that tenders in China have shifted toward local favoritism, and that price has affected win rates, matters as a structural risk. The more placements become “terms-driven,” the more pressure builds at the start of the chain (installations).

2) Whether Ion “placement deceleration” is a phase shift or a demand ceiling

Ion can show periods where placements decline even as utilization grows, which is constructive if it reflects a shift into a “drive utilization at existing customers” phase. Conversely, if it reflects “greater difficulty winning new adoption (competition, budgets, alternative technologies),” then expectations for the future growth runway change.

3) Supply chain / tariff costs spilling into the operating model

Instruments and consumables are a revenue pillar, but they are also exposed to manufacturing footprint and trade conditions. The fact that tariffs are being discussed as a cost factor is worth watching not only for near-term margins, but also because it can feed into hospital cost sensitivity (price increases and contract terms).

4) Volatility in cash generation quality (phases with heavy investment burden)

In recent years, capex has been elevated, and there are years where the FY FCF margin sits toward the lower end of the historical range. That may reflect growth investment, but if heavy investment persists, the gap—“profits grow, but growth in freely usable cash slows”—can last longer. With this dataset, recent TTM FCF cannot be calculated, so no definitive conclusion is made about current conditions.

5) Organizational culture deterioration (ongoing monitoring due to insufficient confirmation)

On employee reviews and related signals, there was limited evidence from reliable primary sources pointing to “clear cultural deterioration.” The right stance is not to conclude “no signs,” but to keep this as an ongoing monitoring item due to insufficient confirmation.

Competitive Landscape: Who does it compete with, what does it win on, and where could it lose?

ISRG’s competition is less a straightforward “hardware performance contest” and more a “surgical infrastructure contest” that becomes embedded in hospital workflows. It’s a comprehensive battle that includes not only the system, but also instruments and consumables, maintenance, training, clinical data, and workflow improvements (software updates).

Key competitive players (companies often used as comparables)

• Medtronic (Hugo): In December 2025, U.S. regulatory clearance for urology use was announced, an important development that expands available options.
• Johnson & Johnson (OTTAVA): In January 2026, a De Novo submission in the U.S. was announced.
• CMR Surgical (Versius): Fundraising and accelerated U.S. expansion have been reported.
• Stryker: Often referenced competitively as part of the broader operating-room equipment ecosystem.
• Other indication-specific players: An industry trend in which multiple surgical-robot-related companies obtained regulatory approvals over the last year.

As a supplement, Ion does not compete on exactly the same playing field as “surgical-assistance robots.” Because it also faces competition across bronchoscopy, image guidance, and biopsy workflow (adjacent domains), the competitive picture can shift depending on the use case.

How competition tends to show up (less full replacement, more coexistence and competition for new placements)

Hospitals’ switching costs tend to be less about the sticker price of the machine and more about operational realities—“training costs,” “reworking OR scheduling,” “aligning peripheral equipment and instruments,” and “issue-response workflows.” As a result, competitive pressure often shows up through incremental placements or domain-by-domain usage (multi-platform adoption) rather than outright replacement (not a definitive claim, but a common structure for medical device platforms).

Moat (Moat): What moat exists, and how durable is it likely to be?

ISRG’s moat is less about patents or standalone technology and more about being embedded in hospital workflows through the accumulation of cases, training, and operating standards. As the installed base expands, training cycles repeat, operations standardize, cases accumulate, and switching costs tend to rise (a structure that can resemble network effects).

That said, the dataset suggests that as competitors advance on the regulatory front, the moat is likely to be challenged not by “disappearing,” but by a shift in how new placements are won (a higher share of terms-driven competition). The change in China’s tender environment may be a representative example.

Structural Position in the AI Era: tailwind or headwind?

ISRG is positioned less on the “gets replaced by AI” side and more on the “becomes stronger as standard operating-room infrastructure while incorporating AI” side. The core value is mission-critical, physical-world surgery, where AI is more likely to be a complement than the primary driver of automation.

Where AI matters: network effects, data advantage, and integration approach

• Network effects: As adoption grows, training and operational standardization deepen, and switching costs tend to rise.
• Data advantage: The edge is less about raw “volume” and more about the ability to “continuously connect improvements on the same platform.” da Vinci 5 is designed to expand intraoperative insights and review functions enabled by computing capability.
• Degree of AI integration: Rather than selling AI as a standalone product, it is integrated step-by-step to fit clinical workflows. In both da Vinci 5 and Ion, AI and imaging integration are embedded as part of the workflow.
• Mission-critical nature: Enhancements that preserve safety, reproducibility, and auditability tend to take priority over flashy automation.

Substitution risk from AI and changes in the competitive map

AI-driven substitution risk appears low, but as AI capabilities advance, the more likely pressure point is “intensified peer competition (features, price, operating terms).” Differentiation shifts from “does it use AI” to “can it be integrated safely into operations” and “does it translate into frontline outcomes.”

Positioning by structural layer

ISRG can be framed as “middle-leaning (physical devices + operating platform) that builds up the application layer (procedure- and indication-specific workflows).” da Vinci 5’s design—“continuous feature additions enabled by computing capability”—improves update resilience in the middle layer and supports long-term accumulation of functionality.

Leadership and culture: “hard-to-see assets” that matter for long-term compounding

Based on public information, ISRG’s leadership messaging has been consistent in emphasizing provider-side outcomes such as “patient outcomes,” “care team experience,” “healthcare costs,” and “access.”

CEO transition (2025) and strategic continuity

• Former CEO Gary Guthart (~June 2025): Even around the time of da Vinci 5 regulatory clearance, he emphasized “meaningful improvements,” “patient outcomes,” “care team experience,” and “total cost of care,” reflecting an approach focused on clinically grounded progress rather than flash.
• New CEO Dave Rosa (July 01, 2025~): The transition appears to be a strongly internal succession rather than an external reset, suggesting strategic continuity. At the same time, it also points to building organizational depth to navigate intensifying competition, a new platform ramp, and tougher region-specific terms.

Generalized profile and how it shows up in culture

Without overstating the case, ISRG can be read as leaning toward “careful, cumulative execution,” “prioritizing meaningful improvements that translate into clinical practice,” and “prioritizing quality, safety, and regulatory compliance, with a focus on making training and operations work.” That fits a model where “utilization and learning” build after installation.

Generalized patterns in employee reviews (trade-offs, not good/bad)

• More likely to show up positively: mission clarity, confidence from rigorous processes, and accumulated expertise across training, clinical, and support functions.
• More likely to show up negatively: rigor can feel like slower decision-making, cross-functional coordination can be costly, and global expansion can make regional requirements, supply, and contract differences more burdensome.

These are framed as cultural trade-offs that often appear in mission-critical, regulated platform businesses.

Fit with long-term investors (culture and governance perspective)

• More likely to fit well: culture (training, maintenance, quality) directly reinforces the revenue model (post-install utilization growth); net cash financials support sustained investment; CEO transition is internal succession, reducing the odds of abrupt strategic pivots.
• Points to watch: as competition increases, new adoption can become more terms-driven, requiring commercial flexibility while protecting quality and operations. In periods where short-term cost factors such as new platform ramp and tariffs overlap, whether optimization can be executed without weakening frontline value.

Two-minute Drill: the long-term investment thesis in “two minutes”

The core way to view ISRG long term is as “healthcare infrastructure that gets stronger the more it’s used after installation.” As installed base and utilization (procedure volume) rise, instruments/consumables and maintenance revenue compound, and standardized training and operations increase switching costs.

• Focus 1: Whether the installed base can keep thickening through accumulated utilization going forward (utilization density, more than installed units, is the core)
• Focus 2: Whether platform refresh (da Vinci 5, etc.) and software upgrades translate not only into more upgraded units, but also into higher utilization and better training efficiency
• Focus 3: Even as competition increases, whether the dynamic remains coexistence and terms competition rather than full replacement, and whether the core position does not materially erode

Meanwhile, at a share price of $523.99, a P/E of 66.1x and PEG of 2.74x are levels that tend to assume “high-quality growth continues.” The key question is less “is it a good company” and more “when competitive conditions, adoption momentum, and cost factors shift, how is the accumulation of utilization explained.”

KPI tree: variables that move ISRG’s value (causal understanding)

Ultimate outcomes (Outcome)

• Long-term profit growth (including EPS)
• Cash generation capability (operating cash flow and the thickness of cash remaining after investment)
• Capital efficiency (ROE, etc.)
• Revenue durability (whether post-install accumulated revenue persists)
• Financial durability (whether it can fund investment and operations without relying on external capital)

Intermediate KPIs (Value Drivers)

• Revenue growth (accumulation of system placements and utilization growth)
• Expansion of the installed base (systems placed and number of facilities)
• Utilization per system (case volume and utilization density)
• Recurring revenue mix (instruments/consumables vs. maintenance/services)
• Margins (especially operating margin)
• Quality of cash conversion (earnings → FCF conversion)
• Upgrade/replacement demand (progress of platform refresh)
• Operational quality of training, maintenance, and supply (no downtime / sustained usability)

Business-line drivers (Operational Drivers)

• da Vinci: new placements, incremental placements, upgrades → accumulation of installed base and maintenance / procedure growth → higher instrument and consumable turnover
• da Vinci 5: staged rollout of software functions and platform refresh → learning and efficiency improvements → higher utilization → higher instrument turnover
• da Vinci SP: expanded indications → more reasons to adopt / expanded use cases at existing facilities → higher utilization
• Consumables and instruments: higher utilization and stable supply → thicker recurring revenue and profit growth
• Maintenance and support: installed base growth and reduced downtime → sustained utilization → sustained instrument revenue
• Ion: installed base expansion and procedure growth, workflow improvements via AI and imaging integration → higher utilization density at existing sites

Constraints (Constraints)

• Heaviness of adoption decision-making (capex, internal coordination, OR scheduling design, training structure)
• Difficulty of utilization design (even if purchased, it may not reach full utilization quickly)
• Phases where price and contract terms become focal points (region, tender environment)
• Supply chain and cost factors (tariffs, etc.)
• Phases with heavy investment burden (capex, etc.)
• Regulatory and safety requirements (speed of rollout and process rigor)

Bottleneck hypotheses (Monitoring Points)

• Balance between installed base growth and utilization growth (misalignment is more likely in Ion)
• Maintaining and improving utilization per system (whether training and OR capacity are constrained)
• Whether platform refresh connects to higher utilization (not ending with upgraded units alone)
• Rising weight of price and procurement terms (regional differences, growth in terms-driven competition)
• Sources of profitability volatility (degree of impact from supply, tariffs, ramp costs)
• Appearance of cash generation (whether the gap between earnings and cash is not persisting)
• Progress of multi-platform adoption (where coexistence begins to matter)